Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic priorities: "We will be the premier glucose sensing solution for all," ...

Analysts expect DexCom to report earnings of $0.6459 per share on revenue of $1.24 billion for the quarter ended December 2025. That would mark a sequential improvement from the third quarter’s $0.61 ...

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 ...

DexCom Inc (DXCM) reports a 13% revenue increase, unveils strategic plans for international growth, and anticipates future challenges in expanding coverage for type 2 non-insulin users.

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full ...

DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...

DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus Estimate of 65 cents by 4.6%. The company reported adjusted earnings of 45 ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over last year's supply shortage of the company's leading diabetes product. Leach ...

Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...